Sorafenib News and Research

RSS

Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).

Researchers determine the novel medical target of angiogenesis for ccRCC patients

Research reported that the DMDRMR/miR-378a-5p/ DAB2IP axis enhances angiogenesis and sunitinib resistance, suggesting that it could be used for patients with ccRCC.

30 May 2022

Study identifies novel targets for treating sorafenib-resistant hepatocellular carcinoma

Research headed by Professor Xiujun Cai used the CRISPR/cas9 system to screen the entire genome of hepatocellular carcinoma cells (HepG2) under sorafenib treatment.

25 Apr 2022

Study identifies new targets for treating sorafenib-resistant hepatocellular carcinoma using CRISPR-Cas9 screening

This study is led by Xiujun Cai (Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine). Professor Xiujun Cai's research team screened the whole genome of hepatocellular carcinoma cells (HepG2) through CRISPR / cas9 system under sorafenib treatment, and screened the dominant gene in sorafenib resistance.

20 Apr 2022